Circulating adiponectin and risk of endometrial cancer

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Zheng, Qiaoli ^a   Wu, Haijian ^a   Cao, Jiang ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; TRIACYLGLYCEROL; ADIPOQ PROTEIN, HUMAN; TUMOR MARKER;

AGE; ARTICLE; ASIA; BODY HEIGHT; BODY MASS; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; COHORT ANALYSIS; DIABETES MELLITUS; DOSE RESPONSE; EDUCATION; ENDOMETRIUM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; GENETIC HETEROGENEITY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; LOW RISK PATIENT; MATHEMATICAL ANALYSIS; PARITY; POPULATION RESEARCH; PREDICTIVE VALUE; PREMENOPAUSE; PUBLISHING; RADIOIMMUNOASSAY; RISK FACTOR; SENSITIVITY ANALYSIS; SMOKING; SUMMARY RELATIVE RISK; WAIST HIP RATIO; BLOOD; ENDOMETRIAL NEOPLASMS; FEMALE; META ANALYSIS;

ADIPONECTIN; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; RISK FACTORS;

EID: 84934977572     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129824     Document Type: Article

References (52)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90. doi: 10.3322/caac.20107 PMID: 21296855
2. Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010; 19: 3119-3130. doi: 10.1158/1055-9965.EPI-10-0832 PMID: 21030602
3. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2569-2578. doi: 10.1158/1055-9965.EPI-09-0372 PMID: 19755644
4. Park J, Euhus DM, Scherer PE. Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev. 2011; 32: 550-570. doi: 10.1210/er.2010-0030 PMID: 21642230
5. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005; 26: 439-451. PMID: 15897298
6. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012; 33: 547-594. doi: 10.1210/er.2011-1015 PMID: 22547160
7. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. Biochem Biophys Res Commun. 2012; 425: 560-564. doi: 10.1016/j.bbrc.2012.08.024 PMID: 22925674
8. Christiansen T, Paulsen SK, Bruun JM, Ploug T, Pedersen SB, Richelsen B. Diet-induced weight loss and exercise alone and in combination enhance the expression of adiponectin receptors in adipose tissue and skeletal muscle, but only diet-induced weight loss enhanced circulating adiponectin. J Clin Endocrinol Metab. 2010; 95: 911-919. doi: 10.1210/jc.2008-2505 PMID: 19996310
9. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003; 46: 459-469. PMID: 12687327
10. Moon HS, Chamberland JP, Aronis K, Tseleni-Balafouta S, Mantzoros CS. Direct role of adiponectin and adiponectin receptors in endometrial cancer: in vitro and ex vivo studies in humans. Mol Cancer Ther. 2011; 10: 2234-2243. doi: 10.1158/1535-7163.MCT-11-0545 PMID: 21980131
11. Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab. 2004; 89: 1160-1163. PMID: 15001602
12. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006; 106: 2376-2381. PMID: 16639730
13. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Lukanova A, et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. J Clin Endocrinol Metab. 2007; 92: 255-263. PMID: 17062769
14. Friedenreich CM, Langley AR, Speidel TP, Lau DC, Courneya KS, Csizmadi I, et al. Case-control study of markers of insulin resistance and endometrial cancer risk. Endocr Relat Cancer. 2012; 19: 785-792. doi: 10.1530/ERC-12-0211 PMID: 23033315
15. Erdogan S, Sezer S, Baser E, Gun-Eryilmaz O, Gungor T, Uysal S, et al. Evaluating vaspin and adiponectin in postmenopausal women with endometrial cancer. Endocr Relat Cancer. 2013; 20: 669-675. doi: 10.1530/ERC-13-0280 PMID: 23896633
16. Luhn P, Dallal CM, Weiss JM, Black A, Huang WY, Lacey JV Jr., et al. Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2013; 22: 1304-1312. doi: 10.1158/1055-9965.EPI-13-0258 PMID: 23696194
17. Ma Y, Liu Z, Zhang Y, Lu B. Serum leptin, adiponectin and endometrial cancer risk in Chinese women. J Gynecol Oncol. 2013; 24: 336-341. doi: 10.3802/jgo.2013.24.4.336 PMID: 24167669
18. Ashizawa N, Yahata T, Quan J, Adachi S, Yoshihara K, Tanaka K. Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. Gynecol Oncol. 2010; 119: 65-69. doi: 10.1016/j.ygyno.2010.07.007 PMID: 20674961
19. Soliman PT, Cui X, Zhang Q, Hankinson SE, Lu KH. Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses' Health Study. Am J Obstet Gynecol. 2011; 204: 167 e161-165.
20. Dallal CM, Brinton LA, Bauer DC, Buist DS, Cauley JA, Hue TF, et al. Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B~FIT cohort. Endocr Relat Cancer. 2013; 20: 151-160. doi: 10.1530/ERC-12-0229 PMID: 23222000
21. Ohbuchi Y, Suzuki Y, Hatakeyama I, Nakao Y, Fujito A, Iwasaka T, et al. A lower serum level of middle-molecular-weight adiponectin is a risk factor for endometrial cancer. Int J Clin Oncol. 2013.
22. Macis D, Guerrieri-Gonzaga A, Gandini S. Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis. Int J Epidemiol. 2014; 43: 1226-1236. doi: 10.1093/ije/dyu088 PMID: 24737805
23. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987; 9: 1-30. PMID: 3678409
24. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009; 172: 137-159. PMID: 19381330
25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21: 1539-1558. PMID: 12111919
26. Cochran WG. The combination of estimates from different experiments Biometrics. 1954; 10: 101-129.
27. Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol. 2012; 175: 66-73. doi: 10.1093/aje/kwr265 PMID: 22135359
28. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50: 1088-1101. PMID: 7786990
29. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634. PMID: 9310563
30. Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab. 2003; 88: 993-997. PMID: 12629074
31. Ali AT. Risk factors for endometrial cancer. Ceska Gynekol. 2013; 78: 448-459. PMID: 24313431
32. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002; 11: 1531-1543. PMID: 12496040
33. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev. 2005; 6: 13-21. PMID: 15655035
34. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002; 8: 731-737. PMID: 12068289
35. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7: 941-946. PMID: 11479627
36. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S, et al. Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int J Cancer. 2004; 108: 262-268. PMID: 14639613
37. Furberg AS, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer. 2003; 104: 669-676. PMID: 12640672
38. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006; 4: 221-233. PMID: 16603636
39. Takemura Y, Osuga Y, Yamauchi T, Kobayashi M, Harada M, Hirata T, et al. Expression of adiponectin receptors and its possible implication in the human endometrium. Endocrinology. 2006; 147: 3203-3210. PMID: 16601138
40. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003; 107: 671-674. PMID: 12578865
41. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000; 102: 1296-1301. PMID: 10982546
42. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 2003; 52: 1779-1785. PMID: 12829646
43. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 2000; 96: 1723-1732. PMID: 10961870
44. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer. 2006; 94: 1221-1225. PMID: 16570048
45. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004; 101: 2476-2481. PMID: 14983034
46. Wang Y, Lam KS, Xu JY, Lu G, Xu LY, Cooper GJ, et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem. 2005; 280: 18341-18347. PMID: 15734737
47. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr. 2007; 86: s858-866. PMID: 18265479
48. Neumeier M, Weigert J, Schaffler A, Wehrwein G, Muller-Ladner U, Scholmerich J, et al. Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol. 2006; 79: 803-808. PMID: 16434692
49. Westerink J, Visseren FL. Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol. 2011; 10: 13. doi: 10.1186/1475-2840-10-13 PMID: 21276223
50. Abbasi F, Chu JW, Lamendola C, McLaughlin T, Hayden J, Reaven GM, et al. Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes. 2004; 53: 585-590. PMID: 14988241
51. Arikoglu H, Ozdemir H, Kaya DE, Ipekci SH, Arslan A, Kayis SA, et al. The Adiponectin variants contribute to the genetic background of type 2 diabetes in Turkish population. Gene. 2014; 534: 10-16. PMID: 24404592
52. Houde AA, Legare C, Hould FS, Lebel S, Marceau P, Tchernof A, et al. Cross-tissue comparisons of leptin and adiponectin: DNA methylation profiles. Adipocyte. 2014; 3: 132-140. doi: 10.4161/adip.28308 PMID: 24719787